

VIA HAND DELIVERY JANUARY 12, 2001

#9  
1-22-01  
P.Z.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Lafleur et al.

Application Serial No.: 09/487,792

Art Unit: 1632

Filed: January 20, 2000

Examiner: Unassigned

For: Keratinocyte Derived Interferon

Attorney Docket No.: PF482P1



**Second Supplemental Information Disclosure Statement**  
**Pursuant to 37 C.F.R. 1.56**

Assistant Commissioner For Patents  
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to the references AA and AB listed on the attached form PTO/SB/08A be made of record in the present application. Copies of references AA and AB are enclosed.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) and 1.106(b) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Identification of the listed references is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b), since this information disclosure statement is being filed before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Science, Inc., deposit account no. 08-3425.

Respectfully submitted,

Date: January 12, 2001

  
Kenley K. Hoover (Reg. No. 40,302)

**Human Genome Sciences, Inc.**  
9410 Key West Avenue  
Rockville, MD 20850  
(301) 610-5771 (telephone)

KKH/CCB/ba